<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Klechevsky E</submitter><funding>NIAID NIH HHS</funding><funding>NCI NIH HHS</funding><pagination>6360-7</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC2728007</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>68(15)</volume><pubmed_abstract>In this study, we have explored the use of Fab-toxin proteins (immunotoxin) to target antigen-specific MHC-peptide complexes of in vitro and in vivo cancer cells. A human phage display library was used to screen for T-cell receptor (TCR)-like antibodies that are highly specific for the peptide melanoma-associated antigen MART-1(26-35) presented by HLA-A201. We also used previously selected TCR-like antibodies specific for the peptide melanoma-associated antigen gp100(280-288) presented by HLA-A201. The recombinant immunotoxin constructs were generated by fusing the targeting Fab fragment to a truncated form of Pseudomonas exotoxin, PE38KDEL. These immunotoxins bound with high affinity to the EBV-transformed JY cell line pulsed with the aforementioned peptides and internalized within 30 min</pubmed_abstract><journal>Cancer research</journal><pubmed_title>Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts.</pubmed_title><pmcid>PMC2728007</pmcid><funding_grant_id>R0-1 CA78846</funding_grant_id><funding_grant_id>P01 CA084512-069004</funding_grant_id><funding_grant_id>P01 CA084512-069002</funding_grant_id><funding_grant_id>P01 CA084512-01A10003</funding_grant_id><funding_grant_id>P0-1 CA84512</funding_grant_id><funding_grant_id>U19 AI057234-03</funding_grant_id><funding_grant_id>U19 AI057234-04</funding_grant_id><funding_grant_id>U19 AI057234-05</funding_grant_id><funding_grant_id>R0-1 CA85540</funding_grant_id><funding_grant_id>U19 AI057234-01</funding_grant_id><funding_grant_id>U19 AI057234-02</funding_grant_id><funding_grant_id>U19 AI057234-010005</funding_grant_id><funding_grant_id>U19 AI057234-010004</funding_grant_id><funding_grant_id>P01 CA084512-020003</funding_grant_id><funding_grant_id>R01 CA085540-02</funding_grant_id><funding_grant_id>R01 CA085540-03</funding_grant_id><funding_grant_id>R01 CA085540-04</funding_grant_id><funding_grant_id>R0-1 CA115550</funding_grant_id><funding_grant_id>U19 AI057234-05S19003</funding_grant_id><funding_grant_id>R01 CA115550-03</funding_grant_id><funding_grant_id>R01 CA115550-04</funding_grant_id><funding_grant_id>R01 CA115550-01</funding_grant_id><funding_grant_id>R01 CA115550-02</funding_grant_id><funding_grant_id>U19 AI057234-05S1</funding_grant_id><funding_grant_id>U19 AI057234-05S10012</funding_grant_id><funding_grant_id>U19 AI057234</funding_grant_id><funding_grant_id>R01 CA078846</funding_grant_id><funding_grant_id>U-19 AI-57234</funding_grant_id><funding_grant_id>R01 CA078846-10</funding_grant_id><funding_grant_id>P01 CA084512</funding_grant_id><funding_grant_id>P01 CA084512-040003</funding_grant_id><funding_grant_id>P01 CA084512-060005</funding_grant_id><funding_grant_id>P01 CA084512-05A29004</funding_grant_id><funding_grant_id>P01 CA084512-05A29002</funding_grant_id><funding_grant_id>R01 CA078846-01A1</funding_grant_id><funding_grant_id>P01 CA084512-05A2</funding_grant_id><funding_grant_id>R01 CA115550</funding_grant_id><funding_grant_id>P01 CA084512-07</funding_grant_id><funding_grant_id>P01 CA084512-030003</funding_grant_id><funding_grant_id>P01 CA084512-06</funding_grant_id><funding_grant_id>R01 CA078846-09</funding_grant_id><funding_grant_id>R01 CA078846-08</funding_grant_id><funding_grant_id>R01 CA078846-07</funding_grant_id><funding_grant_id>P01 CA084512-070005</funding_grant_id><funding_grant_id>R01 CA078846-06</funding_grant_id><funding_grant_id>R01 CA078846-05</funding_grant_id><funding_grant_id>P01 CA084512-05A20005</funding_grant_id><funding_grant_id>R01 CA078846-04</funding_grant_id><funding_grant_id>R01 CA078846-03</funding_grant_id><funding_grant_id>R01 CA078846-02</funding_grant_id><funding_grant_id>R01 CA085540</funding_grant_id><funding_grant_id>P01 CA084512-079002</funding_grant_id><funding_grant_id>R01 CA085540-01A1</funding_grant_id><funding_grant_id>P01 CA084512-079004</funding_grant_id><pubmed_authors>Denkberg G</pubmed_authors><pubmed_authors>Reiter Y</pubmed_authors><pubmed_authors>Klechevsky E</pubmed_authors><pubmed_authors>Gallegos M</pubmed_authors><pubmed_authors>Palucka K</pubmed_authors><pubmed_authors>Cohen C</pubmed_authors><pubmed_authors>Banchereau J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts.</name><description>In this study, we have explored the use of Fab-toxin proteins (immunotoxin) to target antigen-specific MHC-peptide complexes of in vitro and in vivo cancer cells. A human phage display library was used to screen for T-cell receptor (TCR)-like antibodies that are highly specific for the peptide melanoma-associated antigen MART-1(26-35) presented by HLA-A201. We also used previously selected TCR-like antibodies specific for the peptide melanoma-associated antigen gp100(280-288) presented by HLA-A201. The recombinant immunotoxin constructs were generated by fusing the targeting Fab fragment to a truncated form of Pseudomonas exotoxin, PE38KDEL. These immunotoxins bound with high affinity to the EBV-transformed JY cell line pulsed with the aforementioned peptides and internalized within 30 min</description><dates><release>2008-01-01T00:00:00Z</release><publication>2008 Aug</publication><modification>2025-04-04T09:10:34.851Z</modification><creation>2019-03-27T00:24:18Z</creation></dates><accession>S-EPMC2728007</accession><cross_references><pubmed>18676861</pubmed><doi>10.1158/0008-5472.can-08-0928</doi><doi>10.1158/0008-5472.CAN-08-0928</doi></cross_references></HashMap>